These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8156964)

  • 21. [The optimization of the treatment of epilepsy with carbamazepine in puberty].
    Lachkepiani AN; Okudzhava NV; Rukhadze MD
    Zh Nevrol Psikhiatr Im S S Korsakova; 1993; 93(1):32-3. PubMed ID: 8042358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.
    Macphee GJ; McInnes GT; Thompson GG; Brodie MJ
    Lancet; 1986 Mar; 1(8483):700-3. PubMed ID: 2870222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications.
    Bialer M
    Clin Pharmacokinet; 1992 Jan; 22(1):11-21. PubMed ID: 1559305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effect.
    Strandjord RE; Johannessen SI
    Epilepsia; 1980 Dec; 21(6):655-52. PubMed ID: 6777155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.
    Mahmood I; Chamberlin N
    Br J Clin Pharmacol; 1998 Mar; 45(3):241-6. PubMed ID: 9517367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum carbamazepine concentrations following diltiazem initiation.
    Eimer M; Carter BL
    Drug Intell Clin Pharm; 1987 Apr; 21(4):340-2. PubMed ID: 3569036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic comparison of two carbamazepine slow-release formulations.
    Jensen PK; Møller A; Gram L; Jensen NO; Dam M
    Acta Neurol Scand; 1990 Aug; 82(2):135-7. PubMed ID: 2256443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible pitch perception deficit due to carbamazepine.
    Kashihara K; Imai K; Shiro Y; Shohmori T
    Intern Med; 1998 Sep; 37(9):774-5. PubMed ID: 9804087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.
    Larkin JG; McLellan A; Munday A; Sutherland M; Butler E; Brodie MJ
    Br J Clin Pharmacol; 1989 Mar; 27(3):313-22. PubMed ID: 2655682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Monotherapy with carbamazepine in childhood epilepsies].
    Dulac O; Bouguerra L; Rey E; de Lauture D; Arthuis M
    Arch Fr Pediatr; 1983 May; 40(5):415-9. PubMed ID: 6411042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.
    McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse effects from the circadian fluctuations of carbamazepine plasma levels.
    Blennow G
    Acta Paediatr Scand; 1983 May; 72(3):397-401. PubMed ID: 6880726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
    Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
    Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-induced systemic lupus erythematosus after 8 years of treatment with carbamazepine.
    Toepfer M; Sitter T; Lochmüller H; Pongratz D; Müller-Felber W
    Eur J Clin Pharmacol; 1998 Apr; 54(2):193-4. PubMed ID: 9626927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures.
    Benetello P; Furlanut M; Baraldo M; Tonon A; Furlanut M
    Eur Neurol; 2002; 48(4):200-3. PubMed ID: 12422067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).
    Stevens RE; Limsakun T; Evans G; Mason DH
    J Pharm Sci; 1998 Dec; 87(12):1531-4. PubMed ID: 10189261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Exacerbation of seizures by carbamazepine in four children with symptomatic localization related epilepsy].
    Miyamoto A; Takahashi S; Oki J; Itoh J; Cho K
    No To Hattatsu; 1995 Jan; 27(1):23-8. PubMed ID: 7873247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers.
    Wilding IR; Davis SS; Hardy JG; Robertson CS; John VA; Powell ML; Leal M; Lloyd P; Walker SM
    Br J Clin Pharmacol; 1991 Nov; 32(5):573-9. PubMed ID: 1954073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.